Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (NASDAQ: RYZB) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was […]
